Comparing Sevabertinib with Pembrolizumab for HER2 mutation advanced non-small cell lung cancer
Explore this study →
Sites in Brampton, Montreal and 2 more cities
Official title: A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Non-small Cell Lung Cancer, HER2 Mutation · Bayer